We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Antimicrobial Resistance
MedXY News
EnglishTag

Antimicrobial Resistance

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evolving Microbial Landscape and Clinical Profiles in Postcataract Endophthalmitis: Insights from a 23-Year Retrospective Cohort Study
newsclinical presentationmicrobial spectrum

Evolving Microbial Landscape and Clinical Profiles in Postcataract Endophthalmitis: Insights from a 23-Year Retrospective Cohort Study

By MedXY|Sep 13, 2026

This study reveals significant shifts in the bacterial spectrum, antimicrobial resistance, and clinical presentation of acute postcataract endophthalmitis over 23 years, underscoring the need for updated surveillance and tailored treatment

Fecal Microbiota Transplant Fails to Decolonize Multidrug-Resistant Organisms in GI Patients: A Randomized Trial Analysis
GastroenterologyAntimicrobial ResistanceFecal microbiota transplant

Fecal Microbiota Transplant Fails to Decolonize Multidrug-Resistant Organisms in GI Patients: A Randomized Trial Analysis

By MedXY|Apr 27, 2026

A randomized clinical trial found that FMT did not significantly decolonize MDROs or reduce AMR genes in GI disease patients, though it modulated gut microbiome composition.

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions
Clinical UpdatesAntimicrobial ResistanceHelicobacter pylori

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions

By MedXY|Apr 5, 2026

This review synthesizes the evolving landscape of H. pylori management, highlighting the rise of P-CAB-based therapies, the impact of antibiotic resistance on global eradication strategies, and the expanding recognition of extragastric dise

Daily Chlorhexidine Bathing in the ICU: Results from the CLEAN-IT Multicentre Trial
Critical CareAntimicrobial Resistancecritical care

Daily Chlorhexidine Bathing in the ICU: Results from the CLEAN-IT Multicentre Trial

By MedXY|Mar 2, 2026

A large-scale trial in Brazilian ICUs found that daily chlorhexidine bathing did not lower overall nosocomial infection rates but significantly reduced multi-drug resistant pathogen isolation and the use of high-priority reserve antibiotics

Ceftriaxone Resistance in Neisseria gonorrhoeae: Alarming Trends from the 2023 WHO EGASP Surveillance Report
Infectious DiseasesAntimicrobial Resistanceceftriaxone

Ceftriaxone Resistance in Neisseria gonorrhoeae: Alarming Trends from the 2023 WHO EGASP Surveillance Report

By MedXY|Jan 7, 2026

The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accel

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management
Infectious DiseasesAntimicrobial Resistanceclinical trial

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management

By MedXY|Jan 7, 2026

This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.

Optimized Bismuth Quadruple Therapy Surpasses Standard Triple Therapy for First-Line H. pylori Eradication
GastroenterologyAntimicrobial Resistancegastroenterology

Optimized Bismuth Quadruple Therapy Surpasses Standard Triple Therapy for First-Line H. pylori Eradication

By MedXY|Dec 19, 2025

A double-blind RCT in Chile demonstrates that a 14-day optimized bismuth quadruple therapy achieves a 95% eradication rate for Helicobacter pylori, significantly outperforming standard triple therapy without increasing the burden of adverse

Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China
Clinical UpdatesAntimicrobial ResistanceHelicobacter pylori

Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China

By MedXY|Nov 24, 2025

EVEREST-HP demonstrates that rifasutenizol-based triple therapy offers non-inferior H. pylori eradication with improved tolerability compared to bismuth plus clarithromycin triple therapy in treatment-naive Chinese patients.

Deciphering the Impact of Resistance Genes on Antibiotic Efficacy in E. coli: Insights from a Comprehensive Study
Infectious DiseasesAntimicrobial Resistance

Deciphering the Impact of Resistance Genes on Antibiotic Efficacy in E. coli: Insights from a Comprehensive Study

By MedXY|Oct 18, 2025

This study quantifies how specific resistance genes influence minimum inhibitory concentrations in E. coli, enhancing prediction accuracy for antibiotic resistance.

Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature
Clinical Updatesantibiotic stewardshipAntimicrobial Resistance

Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature

By MedXY|Oct 11, 2025

The ARON trial demonstrated that a clinical decision tool combining decision tree, point-of-care CRP testing, and safety-netting advice safely reduces antibiotic prescribing in acutely ill children without delaying recovery or increasing he

Sulopenem versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection: A Comprehensive Clinical Review
Infectious DiseasesAntimicrobial Resistance

Sulopenem versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection: A Comprehensive Clinical Review

By MedXY|Oct 4, 2025

Sulopenem demonstrates noninferior efficacy to amoxicillin/clavulanate in treating uncomplicated UTI with a higher rate of mild adverse events, amidst rising antimicrobial resistance challenges.

Balancing Copper Antimicrobials: A Double-Edged Tool in the Fight Against Antibiotic Resistance
Infectious DiseasesAntimicrobial Resistance

Balancing Copper Antimicrobials: A Double-Edged Tool in the Fight Against Antibiotic Resistance

By MedXY|Oct 2, 2025

Laboratory evolution shows copper exposure can select for antibiotic cross-resistance in Escherichia coli, but resistance may reverse quickly after copper withdrawal — supporting strategic, time-limited use and surveillance of copper-based

Antimicrobial Resistance and Healthcare Costs in Vietnam: Insights from a Six-Year Hospital Study
Infectious DiseasesAntimicrobial Resistancehospital costs

Antimicrobial Resistance and Healthcare Costs in Vietnam: Insights from a Six-Year Hospital Study

By MedXY|Oct 2, 2025

A major Vietnamese tertiary hospital study reveals substantial incremental costs and lengths of stay associated with antimicrobial-resistant ESKAPE pathogens, particularly during the COVID-19 pandemic.

Doxycycline Post-Exposure Prophylaxis Significantly Reduces Bacterial STIs Among MSM and Transgender Women: Final Results from the DoxyPEP Trial
Clinical UpdatesAntimicrobial ResistanceDoxycycline

Doxycycline Post-Exposure Prophylaxis Significantly Reduces Bacterial STIs Among MSM and Transgender Women: Final Results from the DoxyPEP Trial

By MedXY|Oct 1, 2025

The DoxyPEP trial demonstrates that doxycycline post-exposure prophylaxis markedly lowers bacterial STI incidence in men who have sex with men and transgender women, with good tolerability and minimal resistance over 12 months.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story